US2023321271A1PendingUtilityA1

ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

81
Assignee: ABBVIE BIOTHERAPEUTICS INCPriority: May 17, 2016Filed: Feb 22, 2023Published: Oct 12, 2023
Est. expiryMay 17, 2036(~9.8 yrs left)· nominal 20-yr term from priority
Inventors:Christian B. AllanLouie NaumovskiEdward B. Reilly
A61K 47/68035A61K 47/68031A61K 47/6849A61K 31/517A61K 45/06A61K 47/6803A61K 47/6811A61K 47/6871A61K 47/6851A61K 47/68A61K 45/00A61P 35/00A61K 2300/00A61K 47/6857C07K 16/2863
81
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 - 137 . (canceled) 
     
     
         138 . An anti-cMet antibody drug conjugate (“ADC”) consisting of_an anti-cMet antibody (Ab) conjugated to monomethyl auristatin E (“MMAE”) drugs according to the following structure:
                     
 wherein the Ab is an IgG antibody consisting of two heavy chains each consisting of the amino acid sequence of SEQ ID NO: 88 and two light chains each consisting of the amino acid sequence of SEQ ID NO: 89, n has a value of 2, and conjugation of each of the MMAE drugs to the Ab is via a thioether linkage formed with a sulfhydryl group of a cysteine residue. 
 
     
     
         139 . An anti-cMet antibody drug conjugate (“ADC”) consisting of an anti-cMet antibody (Ab) conjugated to monomethyl auristatin E (“MMAE”) drugs according to the following structure:
                     
 wherein the Ab is an IgG antibody consisting of two heavy chains each consisting of the amino acid sequence of SEQ ID NO: 88 and two light chains each consisting of the amino acid sequence of SEQ ID NO: 89, n has a value of 4, and conjugation of each of the MMAE drugs to the Ab is via a thioether linkage formed with a sulfhydryl group of a cysteine residue. 
 
     
     
         140 . A composition comprising an anti-cMet antibody drug conjugate (“ADC”), wherein the ADC consists of an anti-cMet antibody (Ab) conjugated to monomethyl auristatin E (“MMAE”) drugs according to the following structure:
                     
 wherein the Ab is an IgG antibody consisting of two heavy chains each consisting of the amino acid sequence of SEQ ID NO:88 and two light chains each consisting of the amino acid sequence of SEQ ID NO: 89, and conjugation of each of the MMAE drugs to the Ab is via a thioether linkage formed with a sulfhydryl group of a cysteine residue, and 
 wherein the composition has as an average drug-to-antibody ratio (“DAR”) in the range of 2-4. 
 
     
     
         141 . The composition of  claim 140 , having a DAR of about 3.

Join the waitlist — get patent alerts

Track US2023321271A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.